Skip to main content

CATTI and bioMérieux Canada are joining forces to support the development of a qualified workforce in advanced therapies

CATTI, Canadian Advanced Therapies Training Institute, and bioMérieux Canada are combining their respective strengths to enhance the training of the workforce in advanced therapies and the production of quality control solutions (for the pharmaceutical industries).

Through this agreement, bioMérieux will deploy over half a million dollars in analytical equipment and services in the training laboratory at CATTI at the University of Guelph in Ontario, Canada. CATTI is thus adding critical components of control and quality assurance to its state-of-the-art technological environment, crucial for any production under Good Manufacturing Practices (GMP).

This collaboration will address an essential need by training highly qualified personnel (HQP) certified in Good Manufacturing Practices (GMP) and qualified to work under aseptic conditions in the manufacturing of anticancer immunotherapies, cell and gene therapies, vaccines, and other biotherapeutic applications. Learners will develop an understanding and analytical expertise that will enable them to better ensure the safety and efficacy of the therapies they produce throughout their careers.

"bioMérieux is firmly committed to the development of innovative quality control methods for cellular therapies. Establishing a partnership with a training center is an integral part of this strategy," says Michael Reynier, Senior Vice-President, Healht and Personal Care, Industrial Applications, bioMérieux. "The alliance with CATTI will allow us to accelerate the deployment of the most advanced methods to all industry stakeholders in Canada."

"We are very pleased to collaborate with bioMérieux," explains Vanessa Laflamme, CEO of CATTI. "Their contribution of cutting-edge technology equipment will enable us to develop specialized training in analytical methods. Our learners will develop practical skills essential to the biomanufacturing of advanced therapies."

Finally, CATTI and bioMérieux Canada will work together with the industry to identify training needs. This will continuously update the quality of programs offered by CATTI and ensure prioritized content developments synchronized with industry needs.

From left, Patrick Daoust, Chief Business Officer of CATTI ; Vanessa Laflamme, CEO of CATTI ; Pierre Lam, Account Manager Pharma Quality Control of bioMérieux Canada ; Sophie Canobio, Marketing Director Industry of bioMérieux Canada and Craig Hasilo, Chief Scientific Officer of CATTI.